WHAT IS CLAIMED IS:

1. A pharmaceutical composition comprising;

(a) an oxazolidinone antimicrobial agent or a pharmaceutically acceptable salt, ester, or prodrug thereof,

(b) a buffer,

(c) a pH modifier, and

(d) a solvent.

2. A composition according to claim 1 wherein said oxazolidinone antimicrobial agent comprises a pharmaceutically acceptable amount.

3. A composition according to claim 1 wherein said oxazolidinone antimicrobial agent comprises a prophylactically effective amount.

4. A composition according to any of claims 1 to 3 wherein said oxazolidinone antimicrobial agent is radezolid, linezolid, torezolid, or a pharmaceutically acceptable salt or prodrug thereof.

5. A composition according to any of claims 1 to 4 wherein said oxazolidinone antimicrobial agent is radezolid or a pharmaceutically acceptable salt thereof.

6. A composition according to claim 5 wherein said pharmaceutically acceptable salt is a hydrochloride salt.

7. A composition according to any of claims 1 to 3 wherein said oxazolidinone antimicrobial agent is radezolid monohydrochloride.

8. A pharmaceutical composition according to claims 1 to 7 wherein said buffer comprises citric acid and a citric acid salt.

9. A pharmaceutical composition according to claims 1 to 7 wherein said buffer comprises citric acid and sodium citrate tribasic.

10. A pharmaceutical composition according to claims 1 to 9 wherein said pH modifier is selected from sodium hydroxide and phosphoric acid.

11. A pharmaceutical composition according to claims 1 to 10 wherein said pH modifier is sodium hydroxide.

12. A pharmaceutical composition according to claims 1 to 10 wherein said pH modifier is phosphoric acid.

13. A pharmaceutical composition according to claims 1 to 12 wherein said sugar is dextrose.

14. A pharmaceutical composition according to claims 1 to 13 wherein said solvent is water.

15. A pharmaceutical composition comprising

| **Ingredient** | **Mg/mL** |
|---|---|
| Radezolid hydrochloride (amount as hydrochloride salt) | 3.009 |
| Citric acid anhydrous | 4.00 |
| Sodium citrate tribasic (dihydrate) | 1.22 |
| 5% Dextrose solution (D5W) | q.s. |
| 1 Normal Sodium hydroxide or phosphorphic acid | q.s. |
| Total, mg | 1007 |
| Final pH | 3.5 (±0.1) |

16. A pharmaceutical composition comprising

| Ingredient | % (weight/weight) |
|---|---|
| Radezolid hydrochloride (amount as hydrochloride salt) | 0.30% |
| Citric acid anhydrous | 0.40% |
| Sodium citrate tribasic (dihydrate) | 0.12% |
| 5% Dextrose solution (D5W) | q.s. |
| 1 Normal Sodium hydroxide or phosphorphic acid | q.s. |
| Total, mg | 100.00% |
| Final pH | 3.5 (±0.1) |

17. A pharmaceutical composition according to any of claims 1 to 16 for intravenous adminsitration.

18. A pharmaceutical composition according to any of calims 1 to 16 for injectable adminsitration.

19. A method of treating a microbial infection in a patient comprising administering a pharmaceutically effective amount of a pharmaceutical composition according to any of claims 1 to 18.

20. A method of preventing a microbial infection in a patient comprising administering a prophylactically effective amount of a pharmaceutical composition according to any of claims 1 to 18.

21. A method of reducing the risk of a microbial infection in a patient comprising administering a prophylactically effective amount of a pharmaceutical composition according to any of claims 1 to 18.

22. A pharmaceutical composition for treating a microbial infection in a patient according to any of claims 1 to 18.

23. A pharmaceutical composition for preventing a microbial infection in a patient according to any of claims 1 to 18.

24. A pharmaceutical composition for reducing the risk of a microbial infection in a patient according to any of claims 1 to 18.

25. The use of an antibiotic compound in the manufacture of a pharmaceutical composition according to any of claims 1 to 18 for treating a microbial infection in a patient comprising administering a pharmaceutically effective amount of said pharmaceutical composition to said patient.

26. The use of an antibiotic compound in the manufacture of a pharmaceutical composition according to any of claims 1 to 18 for preventing a microbial infection in a patient comprising administering a prophylactically effective amount of said pharmaceutical composition to said patient.

27. The use of an antibiotic compound in the manufacture of a pharmaceutical composition according to any of claims 1 to 18 for reducing the risk of a microbial infection in a patient comprising administering a prophylactically effective amount of said pharmaceutical composition to said patient.

28. A method, composition, or use according to any of claims 19 to 27 wherein said patient is a human or an animal.

29. A method, composition, or use according to any of claims 19-27 wherein said patient is a human.

WHAT IS CLAIMED IS:

1. A method of preventing a microbial infection in a patient comprising administering a prophylactically effective amount of the pharmaceutical composition comprising

(a) an oxazolidinone antimicrobial agent or a pharmaceutically acceptable salt, ester, or prodrug thereof,

(b) a buffer,

(c) a pH modifier, and

(d) a solvent.